Document Type
Article
Publication Date
10-5-2022
Abstract
Epigenetic regulations, that comprise histone modifications and DNA methylation, are essential to processes as diverse as development and cancer. Among the histone post-translational modifications, lysine methylation represents one of the most important dynamic marks. Here, we focused on methyltransferases of the nuclear binding SET domain 1 (NSD) family, that catalyze the mono- and di-methylation of histone H3 lysine 36. We review the loss of function mutations of NSD1 in humans that are the main cause of SOTOS syndrome, a disease associated with an increased risk of developing cancer. We then report the role of NSD1 in triggering tumor suppressive or promoter functions according to the tissue context and we discuss the role of NSD1 in melanoma. Finally, we examine the ongoing efforts to target NSD1 signaling in cancers.
Recommended Citation
Krossa, Imène; Strub, Thomas; Aplin, Andrew E; Ballotti, Robert; and Bertolotto, Corine, "Lysine Methyltransferase NSD1 and Cancers: Any Role in Melanoma?" (2022). Department of Cancer Biology Faculty Papers. Paper 194.
https://jdc.jefferson.edu/cbfp/194
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
PubMed ID
36230787
Language
English
Comments
This article is the author’s final published version in Cancers, Volume 14, Issue 19, October 2022, Article number 4865.
The published version is available at https://doi.org/10.3390/cancers14194865. Copyright © Krossa et al.